The Zacks Analyst Blog Highlights: Disney, Amgen, Booking Holdings, General Motors, and BCE

You’re reading Entrepreneur United States, an international franchise of Entrepreneur Media.

This story originally appeared on Zacks

For Immediate Release

Chicago, IL – November 16, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Walt Disney Co. DIS, Amgen Inc. AMGN, Booking Holdings Inc. BKNG, General Motors Co. GM and BCE Inc. BCE.

– Zacks

Here are highlights from Monday’s Analyst Blog:

Top Analyst Reports for Disney, Amgen and

The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including The Walt Disney Co., Amgen Inc. and Booking Holdings Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Disney have outperformed the Zacks Media Conglomerates industry over the past year (+10.3% vs. -6.3%). The Zacks analyst believes that Disney’s ever expanding international footprint and solid content portfolio has been driving the user growth rate of Disney+.

Disney+ net additions are expected to be higher in the second half of fiscal 2022 from the first half. The upcoming movies, including The King’s Man are anticipated to aid the segment’s prospects. Disney, however, expects to incur elevated costs in fiscal 2022 on the back of expenses due to new projects such as Star Wars: Galaxy’s Edge, Avengers Campus, and the Epcot expansion.

(You can read the full research report on Disney here >>>)

Amgen shares have lost -6% in the year to date period against the Zacks Biomedical and Genetics industry’s loss of -13.7%. Several of AMGN’s marketed drugs have been facing increased pricing headwinds lately. Increasing competition for its legacy products is another headwind.

The Zacks analyst, however, believes that key drugs like Prolia, Repatha, Xgeva and biosimilars have been driving sales. Amgen is rapidly advancing its robust pipeline of early and late-stage assets. Several phase III readouts are due in 2022. The launch of Lumakras, a first-in-class lung cancer treatment, holds a lot of promise even as its label expansion studies have been progressing rapidly.

(You can read the full research report on Amgen here >>>)

Shares of Booking Holdings have gained +10.3% in the past six months against the Zacks Internet Commerce industry’s loss of -7.9%. The Zacks analyst believes that BKNG continues to benefit from an impressive growth trend in the online travel booking market, strength in international markets as well as growth opportunities in the domestic market.

Substantial improvement in its booking trends post removal of travel restrictions is another major tailwind. Booking Holdings experienced solid momentum in Europe in the third quarter. Strong growth across the agency, merchant, and advertising businesses is another positive. Steadily increasing advertising costs, stiff competition in the market, and numerous litigations have been weighing on margins though.

(You can read the full research report on Booking Holdings here >>>)

Other noteworthy reports we are featuring today include General Motors Co. and BCE Inc.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.

Zacks‘ Top Picks to Cash in on Artificial Intelligence

In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create „the world’s first trillionaires.“ Zacks‘ urgent special report reveals 3 AI picks investors need to know about today.

See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN): Free Stock Analysis Report
BCE, Inc. (BCE): Free Stock Analysis Report
The Walt Disney Company (DIS): Free Stock Analysis Report
General Motors Company (GM): Free Stock Analysis Report
Booking Holdings Inc. (BKNG): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert.